Tesamorelin Interactions: Alcohol, Caffeine, Food and Other Compounds

What this page covers

Questions about combining tesamorelin with alcohol, coffee, meals, fasting windows or other medicines are common, but they are not all answerable from published research. This page separates three categories: findings that come from trials and reviews, findings that come from the clinical context in which those trials were run, and reasoning that researchers describe mechanistically because no dedicated interaction study has been published. Each category is labelled explicitly. This page is for educational purposes only and is not medical advice; consult a licensed physician or the prescribing clinician about any question involving tesamorelin, other medicines, alcohol or diet. A broader overview of the compound sits on the PeptideU tesamorelin hub.

What tesamorelin is, and why that shapes interaction questions

Tesamorelin is a prescription medicine, not a research-only material. A 2009 review in Expert Opinion on Investigational Drugs described tesamorelin as a human growth hormone releasing factor analogue then under clinical investigation (PMID 19243281). A 2012 review in The Annals of Pharmacotherapy described tesamorelin as a growth hormone-releasing factor analogue for HIV-associated lipodystrophy and reported that it was given as a 2 mg daily subcutaneous injection in the trials it summarised, with reductions in visceral adipose tissue as the principal reported outcome (PMID 22298602).

Because tesamorelin acts on the growth hormone axis rather than being a classical small-molecule drug cleared by a single hepatic enzyme family, the questions people ask about it — alcohol, caffeine, food timing — map poorly onto the pharmacokinetic interaction studies that exist for oral drugs. Researchers in this field have instead studied tesamorelin in the population it was developed for: adults living with HIV on combination antiretroviral therapy with excess abdominal fat, a population described in a 2010 review of the epidemiology, assessment and management of excess abdominal fat in persons with HIV infection (PMID 20216906).

What the published interaction literature does and does not contain

Across the trials and reviews summarised here — including a 2011 systematic review of placebo-controlled trials of growth hormone axis treatments for HIV-associated lipodystrophy (PMID 21265979) and the 2012 pharmacotherapy review of tesamorelin (PMID 22298602) — the research question was efficacy and tolerability of the drug itself, not co-administration with beverages, foods or recreational substances. The table below states that plainly.

Tesamorelin and alcohol

What studies examined: none of the trials or reviews in this evidence set assigned alcohol, measured alcohol intake as an exposure, or reported an alcohol-by-tesamorelin interaction. That absence is the finding, and it should be stated as such rather than filled in with inference presented as data.

Adjacent evidence: the liver is the organ most often invoked in alcohol questions, and it has been studied in tesamorelin research for separate reasons. A 2017 study in AIDS reported that visceral fat reduction with tesamorelin was associated with improved liver enzymes in people with HIV (PMID 28832410). A 2021 study in Clinical Infectious Diseases reported that growth hormone releasing hormone reduced circulating markers of immune activation in parallel with effects on hepatic immune pathways in individuals with HIV infection and non-alcoholic fatty liver disease (PMID 33852720).

Mechanistic reasoning, labelled as reasoning rather than evidence: researchers note that the diagnostic category studied in that hepatic work — non-alcoholic fatty liver disease and non-alcoholic steatohepatitis — is defined partly by the exclusion of significant alcohol intake, and a 2021 review described NASH as a complex disease with a crowded drug-development landscape (PMID 34588764). The reasoning researchers apply is that alcohol is an independent determinant of hepatic fat and enzyme values, so alcohol intake could confound the liver-related endpoints used in tesamorelin studies. That is an argument about measurement and confounding, not a demonstrated pharmacological interaction, and it has not been tested in a trial in this evidence set.

Tesamorelin and caffeine

What studies examined: no caffeine arm, caffeine-abstinence requirement or caffeine co-administration analysis appears in the tesamorelin trials summarised by the 2012 review (PMID 22298602) or in the 2011 systematic review of placebo-controlled growth hormone axis trials in HIV-associated lipodystrophy (PMID 21265979). There is therefore no published effect size, no reported direction of change, and nothing to summarise beyond the absence itself.

Mechanistic reasoning, labelled as such: growth hormone secretion is pulsatile and partly sleep-associated, and tesamorelin is described as acting on that axis as a growth hormone releasing factor analogue (PMID 19243281). Researchers reasoning from that pharmacology raise the hypothetical that anything altering sleep architecture could in principle alter endogenous secretion patterns. No study in this set measured that hypothesis for caffeine, and framing it as an established interaction would misrepresent the literature.

Food, meal timing and fasting

What studies examined: diet has been studied in this clinical population, but as its own variable. A 2024 analysis in PLOS ONE reported that dietary regimens appeared to possess significant effects on the development of combined antiretroviral therapy-associated metabolic syndrome (PMID 38416754). That study addressed diet and metabolic syndrome risk, not diet as a modifier of tesamorelin pharmacology.

Response variability: a 2015 analysis in PLOS ONE examined predictors of treatment response to tesamorelin, a growth hormone-releasing factor analogue, in HIV-infected patients with excess abdominal fat (PMID 26457580). Work of this kind is how researchers investigate why outcomes differ between participants; it is the closest published analogue to a "does context change the result" question, and it is distinct from an interaction study with a specific food or fasting protocol.

Reasoning, labelled: because tesamorelin is administered by subcutaneous injection rather than orally (PMID 22298602), researchers generally do not expect the first-pass and gastric-emptying issues that drive food-effect studies for oral tablets. That expectation is mechanistic, not an experimental result, and questions about administration timing relative to meals belong with a prescribing clinician.

Antiretroviral therapy and other prescription medicines

The most consistently documented co-exposure in the tesamorelin literature is antiretroviral therapy itself, because the pivotal research population consisted of adults living with HIV with excess abdominal fat (PMID 22298602; PMID 20216906). Trials conducted in people on cART establish that the drug was studied in that setting; they are not formal drug-drug interaction studies with named antiretroviral agents, and the reviews cited here do not report agent-by-agent pharmacokinetic data.

Lipid and cardiovascular context is also relevant to combination questions, because many people in this population take lipid-modifying therapy. A 2017 review in BMC Infectious Diseases surveyed cardiovascular risk and dyslipidemia among persons living with HIV (PMID 28793863). Diagnostic framing for the underlying body-composition condition was addressed in a 2012 article on how to diagnose a lipodystrophy syndrome (PMID 22748602). Neither reported combination outcomes with tesamorelin; they describe the clinical backdrop against which such questions arise.

Adverse Events Raised in Combination Questions: What Studies Report

People asking about combinations often ask whether a second substance amplifies a known adverse effect. The reviewed literature reports adverse events for tesamorelin itself rather than for combinations. The 2012 pharmacotherapy review reported tolerability alongside efficacy for the growth hormone-releasing factor analogue in HIV-associated lipodystrophy (PMID 22298602), and the 2011 systematic review assessed placebo-controlled trials of growth hormone axis treatments in the same population, which is the design that allows adverse events to be compared against placebo (PMID 21265979).

Musculoskeletal and nerve-compression complaints are a recurring topic for growth hormone axis agents. A 2025 pharmacovigilance study in Cureus analysed reports of carpal tunnel syndrome attributed to medication use (PMID 40510111). Pharmacovigilance analyses describe reporting patterns from spontaneous databases; researchers treat them as signal-generating rather than as proof of causation, and that distinction matters when such a signal is invoked in a combination question.

How researchers handle unanswered interaction questions

• They state the gap. Where no co-administration arm existed, the honest summary is that the question was not asked, as is the case across the tesamorelin trials pooled in the 2011 systematic review (PMID 21265979).
• They separate confounding from interaction. Alcohol affecting liver enzymes that are also a tesamorelin study endpoint (PMID 28832410) is a confounding problem, not a demonstrated pharmacological interaction.
• They look for response modifiers. Predictor analyses, such as the 2015 examination of predictors of treatment response to tesamorelin in patients with excess abdominal fat, are how heterogeneity is investigated within existing datasets (PMID 26457580).
• They keep mechanism labelled as mechanism. Reasoning from the growth hormone axis (PMID 19243281) generates hypotheses; it does not generate findings.

Bottom line from the evidence

The published record describes tesamorelin as a prescription growth hormone-releasing factor analogue studied in HIV-associated lipodystrophy, with reported reductions in visceral adipose tissue (PMID 22298602), associated improvements in liver enzymes alongside visceral fat reduction (PMID 28832410) and reductions in circulating immune activation markers with growth hormone releasing hormone in HIV with non-alcoholic fatty liver disease (PMID 33852720). It does not contain alcohol, caffeine or meal-timing interaction trials. Decisions about whether and how tesamorelin is used alongside anything else are clinical decisions for a prescribing physician, and this page is educational only.

References

• Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (The Annals of Pharmacotherapy, 2012)
• Tesamorelin, a human growth hormone releasing factor analogue (Expert Opinion on Investigational Drugs, 2009)
• Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials (HIV Medicine, 2011)
• Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (AIDS, 2017)
• Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease (Clinical Infectious Diseases, 2021)
• Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat (PLOS ONE, 2015)
• Dietary regimens appear to possess significant effects on the development of combined antiretroviral therapy (cART)-associated metabolic syndrome (PLOS ONE, 2024)
• Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease (Drug Design, Development and Therapy, 2021)
• Cardiovascular risk and dyslipidemia among persons living with HIV: a review (BMC Infectious Diseases, 2017)
• Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection (AIDS Reviews, 2010)
• How to diagnose a lipodystrophy syndrome (Annales d'Endocrinologie, 2012)
• Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study (Cureus, 2025)